Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 30.13 CNY -3.06%
Market Cap: 5.3B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Chengdu Easton Biopharmaceuticals Co Ltd stock under the Base Case scenario is 51.11 CNY. Compared to the current market price of 30.13 CNY, Chengdu Easton Biopharmaceuticals Co Ltd is Undervalued by 41%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
51.11 CNY
Undervaluation 41%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Chengdu Easton Biopharmaceuticals Co Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Chengdu Easton Biopharmaceuticals Co Ltd
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for Chengdu Easton Biopharmaceuticals Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about Chengdu Easton Biopharmaceuticals Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

30.13 CNY
-3.06%
-3.06%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Chengdu Easton Biopharmaceuticals Co Ltd
CN
Pharmaceuticals
Market Cap
5.3B CNY
IPO
Sep 2, 2020
Employees
1 188
China
Market Cap
5.3B CNY
Industry
Pharmaceuticals
IPO
Sep 2, 2020
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Chengdu Easton Biopharmaceuticals Co Ltd

Provide an overview of the primary business activities
of Chengdu Easton Biopharmaceuticals Co Ltd.

What unique competitive advantages
does Chengdu Easton Biopharmaceuticals Co Ltd hold over its rivals?

What risks and challenges
does Chengdu Easton Biopharmaceuticals Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide P/S
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide P/E
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide P/OCF
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide P/FCFE
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide P/B
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/S
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/GP
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/EBITDA
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/EBIT
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/OCF
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/FCFF
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide EV/IC
for Chengdu Easton Biopharmaceuticals Co Ltd.

Show me price targets
for Chengdu Easton Biopharmaceuticals Co Ltd made by professional analysts.

What are the Revenue projections
for Chengdu Easton Biopharmaceuticals Co Ltd?

How accurate were the past Revenue estimates
for Chengdu Easton Biopharmaceuticals Co Ltd?

What are the Net Income projections
for Chengdu Easton Biopharmaceuticals Co Ltd?

How accurate were the past Net Income estimates
for Chengdu Easton Biopharmaceuticals Co Ltd?

What are the EPS projections
for Chengdu Easton Biopharmaceuticals Co Ltd?

How accurate were the past EPS estimates
for Chengdu Easton Biopharmaceuticals Co Ltd?

What are the EBIT projections
for Chengdu Easton Biopharmaceuticals Co Ltd?

How accurate were the past EBIT estimates
for Chengdu Easton Biopharmaceuticals Co Ltd?

Compare the revenue forecasts
for Chengdu Easton Biopharmaceuticals Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Chengdu Easton Biopharmaceuticals Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Chengdu Easton Biopharmaceuticals Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Chengdu Easton Biopharmaceuticals Co Ltd compared to its peers.

Compare the P/E ratios
of Chengdu Easton Biopharmaceuticals Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Chengdu Easton Biopharmaceuticals Co Ltd with its peers.

Analyze the financial leverage
of Chengdu Easton Biopharmaceuticals Co Ltd compared to its main competitors.

Show all profitability ratios
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide ROE
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide ROA
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide ROIC
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide ROCE
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Gross Margin
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Operating Margin
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Net Margin
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide FCF Margin
for Chengdu Easton Biopharmaceuticals Co Ltd.

Show all solvency ratios
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide D/E Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide D/A Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Interest Coverage Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Altman Z-Score Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Quick Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Current Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

Provide Cash Ratio
for Chengdu Easton Biopharmaceuticals Co Ltd.

What is the historical Revenue growth
over the last 5 years for Chengdu Easton Biopharmaceuticals Co Ltd?

What is the historical Net Income growth
over the last 5 years for Chengdu Easton Biopharmaceuticals Co Ltd?

What is the current Free Cash Flow
of Chengdu Easton Biopharmaceuticals Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Chengdu Easton Biopharmaceuticals Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Chengdu Easton Biopharmaceuticals Co Ltd

Balance Sheet Decomposition
Chengdu Easton Biopharmaceuticals Co Ltd

Current Assets 1.9B
Cash & Short-Term Investments 1.5B
Receivables 182.4m
Other Current Assets 191.1m
Non-Current Assets 1.5B
Long-Term Investments 81.1m
PP&E 1.3B
Intangibles 84.5m
Other Non-Current Assets 16m
Current Liabilities 661.1m
Accounts Payable 135.1m
Accrued Liabilities 63.5m
Short-Term Debt 227.2m
Other Current Liabilities 235.3m
Non-Current Liabilities 82.2m
Long-Term Debt 39.6m
Other Non-Current Liabilities 42.6m
Efficiency

Earnings Waterfall
Chengdu Easton Biopharmaceuticals Co Ltd

Revenue
1.2B CNY
Cost of Revenue
-254.9m CNY
Gross Profit
899.4m CNY
Operating Expenses
-679.3m CNY
Operating Income
220.1m CNY
Other Expenses
20.5m CNY
Net Income
240.6m CNY

Free Cash Flow Analysis
Chengdu Easton Biopharmaceuticals Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Chengdu Easton Biopharmaceuticals Co Ltd's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive Net Income
Positive Operating Income
54/100
Profitability
Score

Chengdu Easton Biopharmaceuticals Co Ltd's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Chengdu Easton Biopharmaceuticals Co Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
84/100
Solvency
Score

Chengdu Easton Biopharmaceuticals Co Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Chengdu Easton Biopharmaceuticals Co Ltd

Wall Street analysts forecast Chengdu Easton Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Chengdu Easton Biopharmaceuticals Co Ltd is 42.76 CNY with a low forecast of 42.34 CNY and a high forecast of 44.01 CNY.

Lowest
Price Target
42.34 CNY
41% Upside
Average
Price Target
42.76 CNY
42% Upside
Highest
Price Target
44.01 CNY
46% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Chengdu Easton Biopharmaceuticals Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Chengdu Easton Biopharmaceuticals Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one Chengdu Easton Biopharmaceuticals Co Ltd stock?

The intrinsic value of one Chengdu Easton Biopharmaceuticals Co Ltd stock under the Base Case scenario is 51.11 CNY.

Is Chengdu Easton Biopharmaceuticals Co Ltd stock undervalued or overvalued?

Compared to the current market price of 30.13 CNY, Chengdu Easton Biopharmaceuticals Co Ltd is Undervalued by 41%.

Back to Top